Send to

Choose Destination
AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S277-89.

Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.

Author information

VaxGen, Inc., South San Francisco, California 94080, USA.


A new generation of "bivalent" gp120-based vaccines, effective against subtype B and subtype E viruses, has been developed. Antisera from rabbits and humans immunized with these vaccines are able to neutralize macrophage tropic and T-cell tropic viruses grown in activated peripheral blood mononuclear cells (PBMCs). These vaccines are now available for efficacy trials to determine the role of humoral immunity in providing protection against human immunodeficiency virus type 1 (HIV-1) infection.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center